ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,464.62
      -0.16%
      US Tech 100
      19,220.00
      -0.20%
      Dow Jones
      39,150.33
      0.04%
      Brent Oil
      84.39
      0.00%
      Bitcoin
      64,111.79
      -0.21%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. UK
      5. LSE

      6. Ultragenyx Pharmaceutical Inc (0LIF) Quote

      Ultragenyx Pharmaceutical Inc

      Ultragenyx Pharmaceutical Inc (0LIF)

      LSE
      64.79
      0.00
      (0.00%)
      Closed June 23 11:30AM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      64.79
      Bid
      0.00
      Ask
      0.00
      Volume
      32
      0.00 Day's Range 0.00
      64.79 52 Week Range 64.79
      Market Cap
      3.25B
      Previous Close
      64.79
      Open
      -
      Last Trade
      6
      @
      39.4181
      (O)
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      276
      Shares Outstanding
      82,114,000
      Dividend Yield
      -
      PE Ratio
      -5.36
      Earnings Per Share (EPS)
      -7.39
      Revenue
      434.25M
      Net Profit
      -606.64M

      About Ultragenyx Pharmaceutical Inc

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.ultragenyx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0LIF. The last closing price for Ultragenyx Pharmaceutical was $64.79. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of $ 64.79 to $ 64.79.

      Ultragenyx Pharmaceutical currently has 82,114,000 shares outstanding. The market capitalization of Ultragenyx Pharmaceutical is $3.25 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -5.36.

      0LIF Latest News

      More News

      Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

      Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia...

      January 04 2024
      GlobeNewswire Inc.

      Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

      Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) For the...

      December 18 2023
      GlobeNewswire Inc.

      Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

      Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH) Evkeeza è un farmaco, primo nel...

      November 06 2023
      GlobeNewswire Inc.

      Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

      Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza® ist das erste von der U.S. Food and Drug...

      September 01 2023
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10064.7964.7964.7987464.79DE
      40064.7964.7964.7933564.79DE
      120064.7964.7964.7927664.79DE
      260064.7964.7964.7927564.79DE
      520064.7964.7964.7931164.79DE
      1560064.7964.7964.79141164.79DE
      2600064.7964.7964.79120864.79DE

      Market Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AREBAmerican Rebel Holdings Inc
      $ 0.76
      (152.49%)
      		371.46M
      SHCRSharecare Inc
      $ 1.365
      (76.27%)
      		56.33M
      NXLNexalin Technologies Inc
      $ 1.7499
      (59.08%)
      		57.58M
      FUFUBitFuFu Inc
      $ 6.1209
      (56.95%)
      		2.5M
      SPECSpectaire Holdings Inc
      $ 0.50
      (47.06%)
      		65.27M
      FLFVFeutune Light Acquisition Corporation
      $ 2.5502
      (-69.75%)
      		862.38k
      FLFVUFeutune Light Acquisition Corporation
      $ 2.75
      (-66.83%)
      		16.5k
      RWODRedwoods Acquisition Corporation
      $ 2.34
      (-60.34%)
      		155.96k
      KAVLKaival Brands Innovations Group Inc
      $ 1.23
      (-57.14%)
      		4.92M
      RWODURedwoods Acquisition Corporation
      $ 3.24
      (-56.28%)
      		1.47k
      NVDANVIDIA Corporation
      $ 126.57
      (-3.22%)
      		658.13M
      AREBAmerican Rebel Holdings Inc
      $ 0.76
      (152.49%)
      		371.46M
      SIRISirius XM Holdings Inc
      $ 2.94
      (1.38%)
      		330.66M
      AAPLApple Inc
      $ 207.49
      (-1.04%)
      		246.38M
      NKLANikola Corporation
      $ 0.3466
      (5.16%)
      		193.36M

      Discussion

      View Full Feed
      Barauch Barauch 27 seconds ago
      Ask these guys:
      COMPANY OFFICERS & CONTACTS
      Dwight Esnard - CEO
      Michael Layman - CFO
      Jennifer Trowbridge - Legal Counsel
      They have literally destroyed the company and the value of your stock holdings.
      GBHL
      sony12 sony12 40 seconds ago
      AND THE JUDGE SAID GUILTY AS CHARGED IMO
      BDEZ BDEZ 1 minute ago
      ICNM
      ICNM
      JP313 JP313 1 minute ago
      Drawbacks
      The Securities and Exchange Commission warns investors that convertible shares may depress the value of common shares by diluting them.
      2
      Another drawback is that convertible preferred shareholders, unlike common shareholders, rarely have
      DROR
      Truthsocial Truthsocial 1 minute ago
      Good luck to those losers lol
      RDGL
      BDEZ BDEZ 2 minutes ago
      GEGI
      GEGI
      cjstocksup cjstocksup 2 minutes ago
      https://x.com/Travis_4_Trump/status/1804844602127532141
      BDEZ BDEZ 2 minutes ago
      WCVC still waiting on form 10
      12x 12x 2 minutes ago
      It’s interesting that apparently Anavex did the CGI-I measure but did not included it in the outcome measure on the clinical trial.gov. More importantly, how to explain the100x difference (p=0.24 vs p=0.0033) between 2 measures: ADCS-ADL and CGI-I. Recall the RETT trial missed the CGI-I endpoint.
      AVXL
      BDEZ BDEZ 2 minutes ago
      COSM
      COSM
      Monksdream Monksdream 3 minutes ago
      CMND 10Q expected Friday 6/28
      https://investorshub.advfn.com/uimage/uploads/2024/6/23/lyflwIMG_8956.gif
      CMND
      Dust2332 Dust2332 4 minutes ago
      Yes nobody new is able to connect a wallet. I've had multiple people ask me about it even people who were once bashers want to participate.
      TGGI
      Salmiler Salmiler 4 minutes ago
      $TKMO Hey but he will definitely get eyes on it and we know what happens to the stock that has been beaten down for months and all of the sudden gets a huge Influx of cash 💰 we talking moon baby 😉
      TKMO
      puffadder puffadder 5 minutes ago
      IR do you seriously doubt Son of Spiderman
      ASKH
      Monksdream Monksdream 5 minutes ago
      AEMD 10Q expected Thursday 6/27
      https://investorshub.advfn.com/uimage/uploads/2024/6/23/l[ysvIMG_8953.gif
      AEMD
      Eli's Gone Eli's Gone 5 minutes ago
      no...no... a thousand times no...my worst nightmare---I hope Lucas Luetge isn't driving him
      cjstocksup cjstocksup 5 minutes ago
      https://x.com/CollinRugg/status/1804901156344451583
      sab63090 sab63090 5 minutes ago
      I just read what seems logical to me and accept it ....he comes across as an informed biotech investor and supports his views with links, etc. and follows normal medical protocols regarding data release information. I believe he stands firm in his beliefs & knows more than I ever will.
      AVXL
      rich2 rich2 5 minutes ago
      totally agree
      I had some NBRI, and sold it all. I live in California and know the area real well. I have followed for at least 4 years. Something has radically changed so I bought back in. New CEO etc. and rapid analysis of many things needed.

      DO NOT INVEST 1 PENNY UNLESS YOU D
      NBRI
      cjstocksup cjstocksup 6 minutes ago
      https://x.com/OliLondonTV/status/1804663428315029917
      BDEZ BDEZ 6 minutes ago
      BRSH
      BRSH
      BDEZ BDEZ 6 minutes ago
      CRKN
      CRKN
      BDEZ BDEZ 6 minutes ago
      VIRI
      VIRI
      BDEZ BDEZ 6 minutes ago
      VXIT
      VXIT
      BDEZ BDEZ 6 minutes ago
      ENZC
      ENZC

      Your Recent History

      LSE
      0LIF
      Ultragenyx Pharmaceutical
      Delayed Upgrade Clock